# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001654954-23-001778
**Filing Date:** 2023-2
**Character Count:** 30456
**Document Hash:** f7dc3e48c5df9cc43311d0397f0528ee
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-23-001778.hdr.sgml**: 20230215

**ACCESSION NUMBER**: 0001654954-23-001778

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230215

**FILED AS OF DATE**: 20230215

**DATE AS OF CHANGE**: 20230215

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK PLC
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15170
- **FILM NUMBER:** 23634579

**BUSINESS ADDRESS:**
- **STREET 1:** 980 GREAT WEST ROAD
- **CITY:** BRENTFORD MIDDLESEX
- **STATE:** X0
- **ZIP:** TW8 9GS
- **BUSINESS PHONE:** 011442080475000

**MAIL ADDRESS:**
- **STREET 1:** 980 GREAT WEST ROAD
- **CITY:** BRENTFORD MIDDLESEX
- **STATE:** X0
- **ZIP:** TW8 9GS

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **Form 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

 **UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of February 2023

Commission File Number 001-15170

 **GSK plc**

(Translation of registrant's name into English)

 **980 Great West Road, Brentford, Middlesex, TW8 9GS**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

GSK plc (the '**Company**')

 **<u>Vesting of Conditional Share Awards under the Share Value Plan and Sale of Ordinary Shares and American Depositary Shares</u>**

This notification sets out the vesting details for Person Discharging Managerial Responsibilities ('PDMRs') of Conditional Share Awards over Ordinary Shares and American Depositary Shares ('ADSs') made in 2020 under the GlaxoSmithKline Share Value Plan and the subsequent sale of Ordinary Shares and ADSs to meet tax liabilities. The awards, which were conditional on continued employment with the GSK group, vested on 14 February 2023.

Transaction notification

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **1.**<br>| &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | Mr D Jackson | Mr D Jackson |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Position/status | PCA of Ms S Jackson (SVP, Global Communications and CEO Office) | PCA of Ms S Jackson (SVP, Global Communications and CEO Office) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **2.**<br>| &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Nature of the transaction | The vesting of Ordinary Shares awarded in 2020 under the Company's Share Value Plan | The vesting of Ordinary Shares awarded in 2020 under the Company's Share Value Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £0.00<br>| 6330 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; <br> Aggregated volume<br> Price<br>|  |  |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; e)<br>| &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-14 | 2023-02-14 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **1.**<br>| &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | Mr D Jackson | Mr D Jackson |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Position/status | PCA of Ms S Jackson (SVP, Global Communications and CEO Office) | PCA of Ms S Jackson (SVP, Global Communications and CEO Office) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **2.**<br>| &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2020 under the Company's Share Value Plan | The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2020 under the Company's Share Value Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £14.7819<br> .. | 2976 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; <br> Aggregated volume<br> Price<br>|  |  |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; e)<br>| &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-14 | 2023-02-14 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **1.**<br>| &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | Ms S Ramakrishnan | Ms S Ramakrishnan |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Position/status | Chief Digital and Technology Officer | Chief Digital and Technology Officer |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **2.**<br>| &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | American Depositary Shares ('ADSs')<br>ISIN: US37733W2044 | American Depositary Shares ('ADSs')<br>ISIN: US37733W2044 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Nature of the transaction<br>| The vesting of ADSs awarded in 2020 under the Company's Share Value Plan | The vesting of ADSs awarded in 2020 under the Company's Share Value Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | $0.00<br> .. | 5740 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; <br> Aggregated volume<br> Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | &nbsp;&nbsp;&nbsp; Date of the transaction<br>| 2023-02-14 | 2023-02-14 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name<br>| Ms S Ramakrishnan | Ms S Ramakrishnan |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Position/status<br>| Chief Digital and Technology Officer | Chief Digital and Technology Officer |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name<br>| GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; LEI<br>| 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | American Depositary Shares ('ADSs')<br>ISIN: US37733W2044 | American Depositary Shares ('ADSs')<br>ISIN: US37733W2044 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Nature of the transaction | The sale of ADSs to meet tax liabilities on the vesting of awards granted in 2020 under the Company's Share Value Plan | The sale of ADSs to meet tax liabilities on the vesting of awards granted in 2020 under the Company's Share Value Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | $35.9588<br> .. | 3063 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; <br> Aggregated volume<br> Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | &nbsp;&nbsp;&nbsp; Date of the transaction<br>| 2023-02-14 | 2023-02-14 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| New York Stock Exchange (XNYS) | New York Stock Exchange (XNYS) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **1.**<br>| &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | Dr T Wood | Dr T Wood |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Position/status | Chief Scientific Officer | Chief Scientific Officer |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **2.**<br>| &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Nature of the transaction<br>| The vesting of Ordinary Shares awarded in 2020 under the Company's Share Value Plan | The vesting of Ordinary Shares awarded in 2020 under the Company's Share Value Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £0.00<br>| 8314 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; <br> Aggregated volume<br> Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | &nbsp;&nbsp;&nbsp; Date of the transaction<br>| 2023-02-14 | 2023-02-14 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name<br>| Dr T Wood | Dr T Wood |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Position/status<br>| Chief Scientific Officer | Chief Scientific Officer |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name<br>| GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; LEI<br>| 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2020 under the Company's Share Value Plan | The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2020 under the Company's Share Value Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £14.7819<br> .. | 3908 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; <br> Aggregated volume<br> Price<br>|  |  |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; e)<br>| &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-14 | 2023-02-14 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **1.**<br>| &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | Ms V Whyte | Ms V Whyte |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Position/status | Company Secretary | Company Secretary |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **2.**<br>| &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Nature of the transaction<br>| The vesting of Ordinary Shares awarded in 2020 under the Company's Share Value Plan | The vesting of Ordinary Shares awarded in 2020 under the Company's Share Value Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £0.00<br>| 10050 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; <br> Aggregated volume<br> Price<br>|  |  |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; e)<br>| &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-14 | 2023-02-14 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name<br>| Ms V Whyte | Ms V Whyte |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Position/status<br>| Company Secretary | Company Secretary |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **2.**<br>| &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name<br>| GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **3.**<br>| &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| &nbsp;&nbsp;&nbsp; Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2020 under the Company's Share Value Plan | The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2020 under the Company's Share Value Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £14.7819<br> .. | 4724 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; <br> Aggregated volume<br> Price<br>|  |  |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; e)<br>| &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-14 | 2023-02-14 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

---

| | |
|:---|:---|
|  | **GSK plc** |
|  | (Registrant) |
| Date: February 15, 2023 |  |
|  | By:/s/ VICTORIA WHYTE<br> -------------------------- |
|  | Victoria Whyte |
|  | Authorised Signatory for and on |
|  | behalf of GSK plc |

---

<br>